Company Filing History:

14 out of 4,770

Merck + Co., Inc.

patents

3 out of 5,470

The University of Texas System

patents

3 out of 240

The Administrators of the Tulane Educational Fund

patents

4. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2006

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7091380 - N-biphenylmethyl aminocycloalkanecarboxamide derivatives (2006-08-15),

2. 6919343 - N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives (2005-07-19),

3. 6391305 - Conjugates useful in the treatment of prostate cancer (2002-05-21),

4. 6174858 - Conjugates useful in the treatment of prostate cancer (2001-01-16),

5. 6143864 - Peptides (2000-11-07),

6. 6130204 - Peptides (2000-10-10),

7. 5998362 - Conjugates useful in the treatment of prostate cancer (1999-12-07),

8. 5948750 - Conjugates useful in the treatment of prostate cancer (1999-09-07),

9. 5866679 - Peptides (1999-02-02),

10. 5763404 - Methods for using LHRH antagonists with low histamine release (1998-06-09),

11. 5714485 - Piperidine and hexahydropyridazine thrombin inhibitors (1998-02-03),

12. 5681926 - Thrombin receptor binding peptides (1997-10-28),

13. 5672582 - Thrombin inhibitors (1997-09-30),

14. 5510369 - Pyrrolidine thrombin inhibitors (1996-04-23),

15. 5480969 - Antagonists of LHRH (1996-01-02),

Title: Dong-Mei Feng: A Pioneer in Inventing Bradykinin B1 Antagonists

Introduction

Dong-Mei Feng, a prolific inventor hailing from Blue Bell, PA, has made significant contributions to the field of medicine through his groundbreaking inventions. With a total of 18 patents to his name, Dong-Mei Feng is a trailblazer in the world of pharmaceutical innovation.

Latest Patents

Among his latest patents are the N-biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives. These inventions serve as bradykinin B1 antagonists or inverse agonists, playing a crucial role in treating or preventing symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Career Highlights

Dong-Mei Feng has left an indelible mark on renowned companies such as Merck & Company, Inc. and the University of Texas System. His work at these esteemed institutions showcases his expertise and dedication to advancing medical research and technology.

Collaborations

Throughout his career, Dong-Mei Feng has collaborated with esteemed professionals in the field, including Victor M. Garsky and Raymond E. Jones. These collaborations have led to groundbreaking discoveries and have further solidified Dong-Mei Feng's reputation as a leader in pharmaceutical innovation.

Conclusion

In conclusion, Dong-Mei Feng stands as a beacon of innovation in the field of inventing bradykinin B1 antagonists. His relentless pursuit of excellence and passion for creating a better future through technology make him a true pioneer in the industry. Dong-Mei Feng's impact will undoubtedly be felt for generations to come, shaping the future of medicine and pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com